Rapport Therapeutics prices $150 million convertible senior notes offering

• Rapport Therapeutics priced $150 million of 2.25% convertible senior notes due December 1, 2032.
• Underwriters have a 30-day option to purchase another $22.5 million of notes to cover over-allotments.
• Closing is expected around October 30, 2026, with net proceeds of approximately $145 million excluding the option.
• The initial conversion price is approximately $26.775 per share, a 27.5% premium to the concurrent stock offering price.
• Proceeds will primarily support RAP-219 clinical trials, other research and development, working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280600PRIMZONEFULLFEED9854967) on October 28, 2026, and is solely responsible for the information contained therein.